Printed from Voxsanity (voxsanity.com.au) — NCT06911606 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Recruiting
NCT06911606
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing to take part voluntarily and sign a consent form
- Men or women aged between 18 and 75 years old (inclusive)
- People whose small cell lung cancer (SCLC) has been confirmed through a tissue or cell sample (biopsy)
- People whose cancer has been clinically staged as IIB to IIIB (N2) according to a standard cancer staging system (AJCC 8th edition)
- People who have not previously received any systemic cancer treatment or chest radiation therapy
- People whose surgeon has assessed them as having no medical reasons that would prevent surgery
- People who have at least one tumour that can be measured on a scan, according to standard criteria (RECIST 1.1)
- People with a performance status score of 0 or 1 on the ECOG scale, meaning they are fully active or have only minor limitations in physical activity
- People with an expected survival of more than 6 months
- People whose hepatitis B and C status meets specific requirements — certain hepatitis B or C conditions may still allow participation if virus levels are below set thresholds (confirm with trial site)
- People whose blood test results, taken within 7 days before starting the study drug, show that the heart, liver, kidneys, and bone marrow are functioning well enough, without recent use of blood transfusions or certain blood-boosting treatments in the 14 days beforehand
- Women who are either post-menopausal (no period for at least 1 year for confirmed non-medical reasons), have had their ovaries and/or uterus surgically removed, or are of childbearing potential but have had a negative pregnancy test within 7 days before joining and agree to use highly effective contraception (annual failure rate below 1%) or remain abstinent from the time of signing the consent form until at least 6 months after the last dose, and agree not to breastfeed
- Men whose partner is of childbearing age or is pregnant must agree to abstain from heterosexual intercourse or use a condom for at least 6 months during treatment and after the last dose (note: calendar-based or withdrawal methods are not considered acceptable)
- People whose prior non-systemic cancer treatments ended at least 2 weeks before starting this study, and whose treatment-related side effects have mostly resolved (confirm with trial site)
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose biopsy confirms a mixed type of small cell lung cancer
- People who have already received systemic treatment for small cell lung cancer, including chemotherapy, immunotherapy, or radiotherapy
- People who have had another active cancer in the past 5 years or currently have one — though certain fully treated, localised cancers (such as some skin cancers, early-stage bladder cancer, or cervical or breast carcinoma in situ) may still be eligible (confirm with trial site)
- People who are planning to have, or have previously had, an organ or bone marrow transplant
- People with fluid build-up around the lungs, heart, or abdomen that requires medical treatment
- People who have had a heart attack in the past 6 months, or who have a heart rhythm problem that is poorly controlled, including specific abnormal heart rhythm measurements (QTc interval of 450 ms or above for men, or 470 ms or above for women)
- People with uncontrolled or symptomatic high calcium levels in the blood above specified thresholds
- People with moderate or severe nerve damage in the hands or feet (grade 2 or higher peripheral neuropathy)
- People with HIV infection or a positive HIV antibody test result
- People with active tuberculosis
- People with a history of, or current, lung conditions such as interstitial lung disease, pneumoconiosis, radiation-related lung damage, drug-related lung inflammation, or severely reduced lung function, if assessed by the researcher as likely to interfere with the study
- People with active hepatitis B (confirmed by positive surface antigen or core antibody test along with detectable virus levels) or active hepatitis C (confirmed by positive antibody and RNA tests), or co-infection with both hepatitis B and C — note that people with hepatitis B that is well controlled on antiviral treatment may still be eligible (confirm with trial site)
- People with a known active or suspected autoimmune disease that requires systemic immune-suppressing treatment — those whose condition is stable and does not require such treatment may still be considered eligible (confirm with trial site)
- People who have received a live vaccine within 28 days before the first dose — inactivated flu vaccines are permitted, but live nasal flu vaccines are not
- People currently taking systemic corticosteroids (above the equivalent of 10 mg/day of prednisone) or other immune-suppressing medications — low-dose or inhaled steroids and hormone replacement therapy at or below that threshold may be permitted (confirm with trial site)
- People who have had an active infection requiring systemic treatment within 14 days before starting the study drug, or who test positive for COVID-19 (SARS-CoV-2) at enrolment — people with a prior COVID-19 history must have a negative PCR test before the first dose
- People who have had major surgery within 28 days before the first dose, where major surgery is defined as requiring at least 3 weeks of recovery before treatment can begin
- People who have previously been treated with immune checkpoint therapies targeting PD-1, PD-L1, CTLA-4, or similar immune targets
- People currently taking part in another interventional clinical study, or who finished a previous interventional clinical study less than 28 days before starting this one
- People with a known history of severe allergic reactions to any monoclonal antibody treatment
- People with a known allergy to carboplatin, cisplatin, or etoposide (chemotherapy drugs used in this trial)
- Women who are pregnant or breastfeeding
- People with a known history of substance abuse or illicit drug use
- People who, in the researcher's judgement, have other factors that may make it unsafe or unsuitable for them to continue in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: +8616620159730
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Guangdong Provincial People's Hospital
Registry
ClinicalTrials.gov
Start date
22 May 2024
Est. completion
30 June 2026
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
🇨🇳 China
Primary endpoints
pathological complete response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.